Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

EU launches AI-powered real-world data project for cancer therapies
EU launches AI-powered real-world data project for cancer therapies
The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gau...
FDA Grants Fast Track to Palisade Bio’s Drug Candidate
FDA Grants Fast Track to Palisade Bio’s Drug Candidate
The FDA has granted Fast Track designation to Palisade Bio’s investigational drug LB1148 to accelerate the return of bowel function following gastrointestinal surgery. ...
Senators Introduce New Bill to Promote Research and Access to MDMA, Psilocybin
Senators Introduce New Bill to Promote Research and Access to MDMA, Psilocybin

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease
EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease
The European Commission (EC) has granted approval for AbbVie’s Skyrizi (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) to treat moderately to severely ac...
FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congen...
New CRISPR-based tool inserts large DNA sequences at desired sites in cells
New CRISPR-based tool inserts large DNA sequences at desired sites in cells
Building on the CRISPR gene-editing system, MIT researchers have designed a new tool that can snip out faulty genes and replace them with new ones, in a safer and more efficient way. ...
Biovac and IVI enter deal to develop oral cholera vaccine
Biovac and IVI enter deal to develop oral cholera vaccine
South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing ...
Diagnostic marker found for deadly brain disease marked by dementia, movement problems. Discovery could accelerate progress toward therapies for primary tauopathies
Diagnostic marker found for deadly brain disease marked by dementia, movement problems. Discovery could accelerate progress toward therapies for primary tauopathies

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments.

J&J builds case for antidepressant Spravato with head-to-head trial
J&J builds case for antidepressant Spravato with head-to-head trial
Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accele...
FDA Approves New Dosing Schedule for Jazz Pharmaceuticals’ Rylaze
FDA Approves New Dosing Schedule for Jazz Pharmaceuticals’ Rylaze
The FDA has approved Jazz Pharmaceuticals’ supplemental Biologics License Application (sBLA) for an additional dosing schedule for Rylaze (asparaginase erwinia chrysanthemi recombinant) to treat...
FDA Accepts New Data on Apellis’ New Drug Application
FDA Accepts New Data on Apellis’ New Drug Application
The FDA has accepted Apellis Pharmaceuticals’ major amendment to its new drug application (NDA) for pegcetacoplan for the treatment of patients with geographic atrophy secondary to age-related m...
Nona and Dragonfly enter HCAb-based drug discovery partnership
Nona and Dragonfly enter HCAb-based drug discovery partnership

Nona will offer access to its technologies and antibody generation services to Dragonfly for the targets chosen by the latter.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand